Harrow announced its first major market access wins in the 2025 Medicare Part D Prescription Drug Program. Starting Jan. 1, 2025, Vevye will be included in key formularies managed by major plan sponsors such as Express Scripts, Cigna, Kaiser Permanente, and CVS Caremark. In the aggregate, these sponsors represent over 25 million Medicare Part D beneficiaries. In addition to Medicare Part D, Vevye has achieved broad coverage across other major insurance programs, including 100% of U.S. Medicaid programs and 60% of commercial insurance coverage.

In other news, Harrow announced an innovative initiative to expand access and affordability for its ophthalmic pharmaceutical products. This effort includes a program of targeted price reductions for several Harrow products and a strategic partnership with GoodRx, providing patients with discounts on select Harrow products.